Sun Pharma’s Biggest Global Bet, Buys Organon in $11.75 Billion Deal; Pharma Stock Surge 7% - Time to Buy?

Sun Pharmaceutical Industries has announced a significant global acquisition, entering into a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at around $11.75 billion. The deal, priced at $14 per share, marks a major expansion move for India's largest pharmaceutical company as it looks to strengthen its global footprint and diversify its portfolio.

Sun Pharma Acquires Organon in $11.75 Billion Deal

The proposed acquisition is one of the largest cross-border deals by an Indian pharma firm in recent years. Sun Pharma stated that the move aligns with its long-term strategy of expanding its innovative medicines business while reinforcing its presence in branded generics and established medicines.

The transaction has already received approval from the boards of both companies and will now proceed subject to regulatory clearances and approval from Organon's shareholders.

Know About Organon: Global Women's Health and Biosimilars Player

Organon was spun off from Merck & Co. in 2021 and has since established itself as a key player in women's health and general medicines. The company has a portfolio of more than 70 products, including biosimilars, and operates across over 140 countries.

Its major markets include the United States, Europe, China, Canada and Brazil. Organon's global reach is supported by six manufacturing facilities across the European Union and emerging markets, giving it strong operational scale and distribution capabilities.

Sun Pharma highlighted that the acquisition will strengthen its position in multiple segments. By integrating Organon's portfolio, the combined entity is expected to gain scale in established brands and enter the fast-growing biosimilars segment as a top global player.

The company also noted that Organon's strong stakeholder relationships and international presence would complement its existing strengths, helping improve market access and long-term growth prospects.

Commenting on the development, Dilip Shanghvi said the transaction is a strategic step towards building a more diversified global platform. He emphasised that Organon's capabilities and product portfolio align well with Sun Pharma's vision of expanding access to healthcare while driving sustainable growth.

Sun Pharma Share Price Today

Shares of Sun Pharmaceutical Industries Limited witnessed a strong rally on April 27, 2026, reflecting positive investor sentiment following recent developments. The stock was trading at Rs 1,736.70, marking a sharp gain of 7.18% or Rs 116.30 during the session.

The stock opened at Rs 1,625.00 and moved higher through the day, touching an intraday high of Rs 1,766.90. On the downside, it recorded a low of Rs 1,621.90, indicating sustained buying interest across levels.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.